Advances in the computational landscape for repurposed drugs against COVID-19

被引:18
|
作者
Aronskyy, Illya [1 ]
Masoudi-Sobhanzadeh, Yosef [2 ]
Cappuccio, Antonio [1 ]
Zaslavsky, Elena [1 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA
[2] Tabriz Univ Med Sci, Res Ctr Pharmaceut Nanotechnol, Biomed Inst, Tabriz, Iran
基金
美国国家卫生研究院;
关键词
Computational drug repurposing; COVID-19; SARS-CoV-2; Docking and molecular dynamics; Structure-guided machine learning; Virus-host interaction network analysis; CORONAVIRUS; DOCKING; COMPLEMENT; SARS-COV-2; KNOWLEDGE; HELICASE; DATABASE; BINDING; DESIGN;
D O I
10.1016/j.drudis.2021.07.026
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The COVID-19 pandemic has caused millions of deaths and massive societal distress worldwide. Therapeutic solutions are urgently needed, but de novo drug development remains a lengthy process. One promising alternative is computational drug repurposing, which enables the prioritization of existing compounds through fast in silico analyses. Recent efforts based on molecular docking, machine learning, and network analysis have produced actionable predictions. Some predicted drugs, targeting viral proteins and pathological host pathways are undergoing clinical trials. Here, we review this work, highlight drugs with high predicted efficacy and classify their mechanisms of action. We discuss the strengths and limitations of the published methodologies and outline possible future directions. Finally, we curate a list of COVID-19 data portals and other repositories that could be used to accelerate future research.
引用
收藏
页码:2800 / 2815
页数:16
相关论文
共 50 条
  • [31] Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies
    Piplani, Sakshi
    Singh, Puneet Kumar
    Winkler, David A.
    Petrovsky, Nikolai
    MOLECULAR BIOMEDICINE, 2021, 2 (01):
  • [32] Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies
    Sakshi Piplani
    Puneet Kumar Singh
    David A. Winkler
    Nikolai Petrovsky
    Molecular Biomedicine, 2
  • [33] Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review
    Acharya, Yogesh
    Sayed, Abida
    THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2020, 7
  • [34] Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19
    Kaliamurthi, Satyavani
    Selvaraj, Gurudeeban
    Selvaraj, Chandrabose
    Singh, Sanjeev Kumar
    Wei, Dong-Qing
    Peslherbe, Gilles H.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (13)
  • [35] Theoretical study of chemical reactivity descriptors of some repurposed drugs for COVID-19
    Morad, Razieh
    Akbari, Mahmood
    Maaza, Malik
    MRS ADVANCES, 2023, 8 (11) : 656 - 660
  • [36] Potential repurposed SARS-CoV-2 (COVID-19) infection drugs
    Abuo-Rahma, Gamal El-Din A.
    Mohamed, Mamdouh F. A.
    Ibrahim, Tarek S.
    Shoman, Mai E.
    Samir, Ebtihal
    Abd El-Baky, Rehab M.
    RSC ADVANCES, 2020, 10 (45) : 26895 - 26916
  • [37] Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs
    Badary, Osama A.
    PHARMACOGENOMICS JOURNAL, 2021, 21 (03): : 275 - 284
  • [38] Theoretical study of chemical reactivity descriptors of some repurposed drugs for COVID-19
    Razieh Morad
    Mahmood Akbari
    Malik Maaza
    MRS Advances, 2023, 8 : 656 - 660
  • [39] A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19
    Kushwaha, Narva Deshwar
    Mohan, Jivanka
    Kushwaha, Babita
    Ghazi, Terisha
    Nwabuife, Joshua C.
    Koorbanally, Neil
    Chuturgoon, Anil A.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 260
  • [40] A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19
    Banerjee, Surojit
    Banerjee, Debadri
    Singh, Anupama
    Kumar, Sumit
    Pooja, Deep
    Ram, Veerma
    Kulhari, Hitesh
    Saharan, Vikas Anand
    VACCINES, 2023, 11 (02)